Geng Xiao-Xia, Yang Qin, Xie Ru-Jia, Luo Xin-Hua, Li Cheng-Xiu, Cheng Ming-Liang
Department of Infectious Diseases, Affiliated Hospital of Guiyang Medical College, Guizhou 550004, China.
Hepatobiliary Pancreat Dis Int. 2004 Nov;3(4):558-63.
Hepatic fibrosis is the common pathological change in various chronic liver diseases, and its major cause is the imbalance between the production and degradation of the extracellular matrix, which is mainly composed of collagens. Dan-Shao-Hua-Xian (DSHX) capsule, a traditional Chinese herbal compound, has shown marked preventive effects on hepatic fibrosis in rats in our previous studies. The present study was designed to further investigate its therapeutic actions on hepatic fibrosis in rats and its possible mechanisms.
Eighty male Wistar rats were randomly divided into normal control group, hepatic fibrosis group, non-DSHX-treated group, low-dose-treated group, and high-dose-treated group. The rat models of hepatic fibrosis were established by subcutaneous injecton of CCl4, drinking alcohol, giving diet of hyperliprosis and hypoprotein for 8 weeks. The two DSHX-treated groups were treated respectively with low dose (0.5 g/kg) and high dose (1.0 g/kg) of DSHX capsule p.o. everyday for 8 weeks. At the end of the experiment, liver indexes were calculated in each group in addition to the levels of the serum hyaluronic acid and alanine aminotransferase. Their degree of hepatic fibrosis and urinary excretion of hydroxyproline and expression of collagen I, III were detected.
Comparison of the indexes of the hepatic fibrosis group and non-DSHX-treated group revealed that the liver indexes, levels of serum hyaluronic acid and alanine aminotransferase, and stage of hepatic fibrosis were all significantly reduced in the two DSHX treated groups. The urinary excretion of hydroxyproline was increased and the expression of collagen I and III in liver tissue was lessened. These alterations were more obviously observed in the high-dose-treated group.
DSHX capsule has certain therapeutic effect on hepatic fibrosis in rats.
肝纤维化是各种慢性肝病的常见病理变化,其主要原因是细胞外基质(主要由胶原蛋白组成)的产生与降解失衡。丹芍化纤(DSHX)胶囊是一种传统中药复方制剂,在我们之前的研究中已显示出对大鼠肝纤维化具有显著的预防作用。本研究旨在进一步探讨其对大鼠肝纤维化的治疗作用及其可能的机制。
80只雄性Wistar大鼠随机分为正常对照组、肝纤维化组、未用DSHX治疗组、低剂量治疗组和高剂量治疗组。通过皮下注射四氯化碳、饮酒、给予高脂低蛋白饮食8周建立大鼠肝纤维化模型。两个DSHX治疗组分别每天口服低剂量(0.5 g/kg)和高剂量(1.0 g/kg)的DSHX胶囊,持续8周。实验结束时,除计算每组的肝脏指数外,还检测血清透明质酸和丙氨酸转氨酶水平。检测其肝纤维化程度、羟脯氨酸尿排泄量以及I、III型胶原蛋白的表达。
肝纤维化组与未用DSHX治疗组指标比较显示,两个DSHX治疗组的肝脏指数、血清透明质酸和丙氨酸转氨酶水平以及肝纤维化分期均显著降低。羟脯氨酸尿排泄量增加,肝组织中I、III型胶原蛋白的表达减少。在高剂量治疗组中这些变化更明显。
DSHX胶囊对大鼠肝纤维化有一定治疗作用。